dCasMINI-mediated therapy rescues photoreceptors degeneration in a mouse model of retinitis pigmentosa

Retinitis pigmentosa (RP) is characterized by degeneration of rod and cone photoreceptors that progresses to irreversible blindness. Now, there are no mutation-agnostic approaches to treat RP. Here, we utilized a single adeno-associated virus (AAV)-based CRISPR activation system to activate phosphodiesterase 6B (Pde6b) to mitigate the severe degeneration in <i>Pde6a</i><sup>nmf363</sup> mice. We demonstrate that transcriptional activation of <i>Pde6b</i> can rescue the loss of <i>Pde6a</i>, with preservation of retinal structure, restoration of electroretinography responses, and improvement of visual function as assessed by optokinetic response and looming-induced escape behaviors. These findings demonstrate the therapeutic potential of a dCasMINI-mediated activation strategy that provides a mutation-independent treatment for retinal degeneration. This study offers a promising therapeutic approach for RP and potentially other forms of genetic diseases.

Authors

Institutions

Publication Details

Journal
Science Advances
Published
2024-12-18
DOI
https://doi.org/10.1126/sciadv.adn7540
Citations
4
Primary Topic
Retinal Development and Disorders
Type
article
Field-Weighted Citation Impact
0.94
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

dCasMINI-mediated therapy rescues photoreceptors degeneration in a mouse model of retinitis pigmentosa

Sui Wang, Lei S. Qi, Zhiquan Liu, M. Elizabeth Hartnett et al.
4 citations
Science Advances
Retinal Development and Disorders
0.94
article

dCasMINI-mediated therapy rescues photoreceptors degeneration in a mouse model of retinitis pigmentosa

Sui Wang, Lei S. Qi, Zhiquan Liu, M. Elizabeth Hartnett, Xiaoshu Xu, Yang Sun, Ke Ning, Tia J. Kowal, Siyu Chen, Chien‐Hui Lo, Liang Li, Biao Wang, Rui Lu, Tingting Li, Qing Wang
article en
4 citations

Abstract

Retinitis pigmentosa (RP) is characterized by degeneration of rod and cone photoreceptors that progresses to irreversible blindness. Now, there are no mutation-agnostic approaches to treat RP. Here, we utilized a single adeno-associated virus (AAV)-based CRISPR activation system to activate phosphodiesterase 6B (Pde6b) to mitigate the severe degeneration in <i>Pde6a</i><sup>nmf363</sup> mice. We demonstrate that transcriptional activation of <i>Pde6b</i> can rescue the loss of <i>Pde6a</i>, with preservation of retinal structure, restoration of electroretinography responses, and improvement of visual function as assessed by optokinetic response and looming-induced escape behaviors. These findings demonstrate the therapeutic potential of a dCasMINI-mediated activation strategy that provides a mutation-independent treatment for retinal degeneration. This study offers a promising therapeutic approach for RP and potentially other forms of genetic diseases.

Science AdvancesVol. 10(51)
Palo Alto University (US), Palo Alto Veterans Institute for Research (US), Stanford Health Care (US), Chan Zuckerberg Initiative (United States) (US), Shanghai East Hospital (CN), Stanford Medicine (US), Smith-Kettlewell Eye Research Institute (US), Stanford University (US)
Life in Land
Openalex Percentile: Top 24%
Retinal Development and Disorders
0.94
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.